Roche has reported a significant milestone in its drug development pipeline, with its candidate Fenebrutinib delivering strong results in a major late-stage clinical trial for multiple sclerosis. This success raises questions about whether it can provide sustained momentum for the stock, which recently paused after a notable rally.
A Solid Foundation for Future Growth
The positive news stems from the FENhance 1 trial, which evaluated Fenebrutinib in patients with relapsing multiple sclerosis (RMS). Data indicates the drug significantly reduced the annualized relapse rate when measured against an established standard therapy. This marks the third successful Phase III study for this investigational treatment, strengthening Roche’s competitive stance in the lucrative MS therapeutics market.
This achievement is part of a broader pattern of operational progress. In February, Swissmedic granted approval for the company’s drug Gazyvaro to treat lupus nephritis. These consistent outputs from its research division bolster the long-term growth narrative for the Basel-based pharmaceutical giant.
Market Performance and Technical Perspective
The market’s response to the trial data has been measured. After reaching a new 52-week high of €409.45 on February 24, Roche shares entered a phase of consolidation. The closing price on Tuesday stood at €396.75. Despite this recent slight pullback, the stock’s performance in 2024 remains robust, showing a gain of approximately 12.8% since the start of the year.
Should investors sell immediately? Or is it worth buying Roche?
From a technical analysis viewpoint, conditions have stabilized following the earlier rapid ascent. The Relative Strength Index (RSI) has retreated to a reading of 35.6, suggesting the previous overbought pressure has eased. Furthermore, the share price continues to trade comfortably above its 200-day moving average of €313.87, confirming the underlying long-term upward trend remains intact.
Key Events on the Horizon
Company leadership has reaffirmed its 2026 targets, which include mid-single-digit percentage sales growth. Investors are now looking ahead to two imminent events that could influence share price volatility. The Annual General Meeting is scheduled for March 10. Deeper insights into business performance will follow with the release of first-quarter sales figures on April 23.
Analysts suggest that if the stock can establish support above its 50-day moving average near €376, the bullish outlook for the spring season is likely to be maintained.
Ad
Roche Stock: Buy or Sell?! New Roche Analysis from March 4 delivers the answer:
The latest Roche figures speak for themselves: Urgent action needed for Roche investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 4.
Roche: Buy or sell? Read more here...
